NV-KALRAY
Kalray (Euronext Growth Paris: ALKAL), a technology innovator building software and hardware solutions that accelerate data-intensive workflows, announced Ngenea® for AI, a new edition of its Kalray Data Acceleration Platform specifically fine-tuned for AI data pipelines. As AI demands new ways to ingest and access massive volumes of data, Ngenea for AI helps teams speed up performance, simplify data management and open their data assets to new AI-powered use cases.
Ngenea for AI is the companion to two Ngenea editions for Media & Entertainment and HPC customers, respectively. The new Ngenea for AI empowers AI innovators to speed up their ingest performance and access their unstructured data from a unified, global name space. Kalray debuted Ngenea for AI at Dell Technologies World 2024 in Las Vegas today, where the software’s performance on Dell servers is being showcased in the Kalray Booth #1026.
The generative AI (GenAI) market is predicted to see 42% compound annual growth rate (CAGR) across the next 10 years into a $1.3 trillion space, from just $40 billion in 2022 (Bloomberg Intelligence). Yet innovative AI constructs such as large language models (LLMs) and Retrieval-Augmented Generation (RAG), and applications including Smart Vision and GenAI, are challenging the ability of IT systems to move data to and from their massive data stores.
ENABLING GENAI AND RAG
Ngenea for AI adds data indexing and search capabilities, which users can leverage to feed any data to Smart Vision, GenAI and RAG applications effortlessly. The new offering enables AI customers to fully harness their existing assets when deploying GenAI applications, regardless of where the data is stored. These GenAI and RAG capabilities simplify and automate what would otherwise be a complex workflow from a data management aspect.
”Fast AI processing is mission-critical to our business of detecting railcar anomalies before they lead to breakdowns or derailments. With Ngenea deployed along with Dell Technologies products, Duos achieved a 120x performance boost on our Railcar Inspection Portal (RIP®) solution, and an 8x increase in inspection accuracy. Working with Kalray helped us put railroads at the forefront of innovation,” said Jeff Necciai, chief technology officer of Duos Technologies.
HIGH-PERFORMANCE STORAGE TIER TO FEED GPUS EFFORTLESSLY
The Ngenea for AI platform also incorporates a high-performance storage tier for the most data-intensive AI workloads. The tier is powered by a proven high-performance parallel file system that can easily manage petabytes of data and billions of files – whether data live on the edge, in the cloud, or on premises. This allows customers and partners to maximize the value of their GPU investment, without rip-and-replace deployments.
With Ngenea, AI innovators:
- Accelerate AI workflows by optimizing AI data pipelines and enhancing the overall speed and efficiency of AI operations.
- Boost the AI model performance by feeding data to GPUs faster, allowing for quicker computations and accelerated insights.
- Gain advanced data indexing capabilities that enable Generative AI and RAG applications to deliver more refined search functionalities, enabling more effective queries and a more strategic utilization of AI models.
- Facilitate a controlled and optimized connection between company data and a suite of third-party AI-powered tools, ensuring seamless integration and data synergy.
Optional hardware acceleration via Kalray’s DPUs including the TURBOCARD4 (TC4) allows parallel processing in an asynchronous way for ultra-demanding workflows, via a complementary architecture to GPUs.
“Even with the tremendous commitment that C-suite leaders are making to AI, very few CIOs have the sizable budgets required to deploy a new system solely for an AI rollout,” said Scott Sinclair, practice director, infrastructure, and modernization, at the Enterprise Strategy Group TM. “Innovative use cases that enable enterprises to leverage their existing infrastructure and still deploy novel AI applications address a sizable untapped need in the market.”
AI TOOLKIT FOR EASY INTEGRATION
Ngenea for AI includes an AI Toolkit that Kalray partners can use for easy integration of their applications with Ngenea. For example, when integrating Ngenea with Perifery Vision AI, users can intuitively search for historical content across a vast amount of data on locations, types, and collections.
“Traditional data centers weren’t built for massive data sets found in AI workloads – or to process these workloads rapidly and efficiently,“ said Eric Baissus, CEO of Kalray. “Kalray’s Ngenea for AI is the data acceleration platform for the AI age – software that elevates performance on existing servers and storage and provides toolkits that streamline application integration. With our software, enterprises and service providers can feed GPUs effortlessly - optimizing data movement and orchestration as the foundation of their infrastructure - so that AI genuinely delivers a competitive edge.“
The Ngenea for AI platform joins two other Ngenea editions that streamline application integration for specific use cases: Ngenea for HPC – providing scratch storage, or storage for temporary user data, and Ngenea for Media & Entertainment – to accelerate post-production workflows.
Ngenea for AI is available today from Dell, from Kalray and select partners. For more information visit here.
ABOUT KALRAY
Kalray is a technology innovator specializing in software and hardware solutions to accelerate data-intensive workflows in Media & Entertainment, High-Performance Computing, and Artificial Intelligence. Our comprehensive product range features Ngenea, a leading data acceleration platform, as well as accelerated data processing cards for storage and compute.
With Kalray solutions, customers can scale their infrastructures to efficiently meet the performance and capacity needs of data-intensive tasks, all without being tied to specific data formats or vendors.
Founded in 2008 as a spin-off from the French CEA research lab, Kalray has corporate and financial backing from notable investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors, and Bpifrance. Committed to innovation and excellence, we strive to deliver value to our customers, developers, and the planet through technology and expertise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521509685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
